peptides for FAQ

True recomposition at maintenance calories (zero net weight change while fat decreases and muscle increases) is biochemically difficult but achievable with precise peptide selection. The protocol requires compounds that enhance nutrient partitioning—shifting ingested calories toward muscle protein synthesis rather than fat storage. Research using MK-677 (a ghrelin mimetic) at 25 mg daily demonstrated this exact outcome: subjects maintained stable body weight over 16 weeks while DEXA scans showed 1.1 kg lean mass gain and 1.3 kg fat mass loss. The mechanism involves elevated IGF-1 driving muscle protein synthesis while increased growth hormone pulses enhance lipolysis during fasted periods. Maintenance recomposition requires higher protein intake (2.2–2.6 g/kg) and progressive resistance training—the peptides create the hormonal environment, but mechanical tension and amino acid availability are what actually build tissue.

Yes, but the mechanism shifts. At body fat levels below 12% (men) or 20% (women), the body's adaptive responses to caloric deficit become more aggressive—leptin drops sharply, ghrelin stays elevated longer, and thyroid output decreases to preserve remaining fat stores. GH secretagogues become particularly valuable at this stage because they maintain IGF-1 levels that would otherwise crash, preventing muscle catabolism even as fat loss slows. Research using ipamorelin in lean subjects (BMI 20–23) showed that lean mass was preserved even during 20% caloric deficits sustained for eight weeks, whereas control groups lost measurable muscle mass. The fat loss rate was slower than in higher-body-fat subjects, but the recomposition ratio (percentage of weight lost coming from fat vs muscle) was actually better—94% fat vs 6% lean compared to 85% fat vs 15% lean in subjects starting above 25% body fat.

Investigate immune recalibration compounds first—specifically Thymosin Alpha 1 or Thymalin. Research protocols typically begin with baseline cytokine profiling (IL-6, TNF-alpha, IFN-gamma) to confirm ongoing immune activation, then administer Thymosin Alpha 1 at 1.6mg subcutaneous twice weekly for 12–16 weeks. The mechanism targets dendritic cells and regulatory T-cell function, pathways that remain dysregulated long after bacterial clearance. Response markers include reduction in pro-inflammatory cytokines and improved CD4+/CD8+ ratios, measurable through serial blood draws at 4, 8, and 12 weeks.

Consider BPC-157 to address gut-brain axis disruption. Research suggests Borrelia infection compromises intestinal barrier integrity, increasing lipopolysaccharide (LPS) translocation into systemic circulation—driving both neuroinflammation and systemic cytokine activation. BPC-157 promotes angiogenesis and accelerates mucosal healing in the GI tract while modulating the vagus nerve signaling that connects gut inflammation to brain function. Typical research protocols use 250–500mcg subcutaneous daily for 4–8 weeks, with symptom tracking focused on both GI function (Bristol stool scale, abdominal pain scores) and cognitive clarity.

Verify receptor expression in your cell line or tissue model first. If the target cells don't express KISS1R, exogenous kisspeptin won't produce a response regardless of dose. Next, confirm the peptide is reaching the target compartment: peptides >3 kDa don't cross cell membranes efficiently, so if you're studying an intracellular target, you need cell-penetrating peptide (CPP) conjugation or electroporation. Finally, check whether your readout is downstream enough. GnRH stimulates LH secretion within 30 minutes, but downstream effects like steroidogenesis take 4–6 hours. Measuring too early or too late in the signaling cascade produces false negatives.

Discard the vial immediately—cloudiness or visible particles indicate aggregation, precipitation, or microbial contamination. Peptides are soluble in aqueous solution at physiological pH; cloudiness suggests the peptide has aggregated due to incorrect reconstitution pH, excessive agitation, or temperature shock (reconstituting with ice-cold water into a room-temperature vial). Aggregated peptides cannot bind receptors properly and may trigger immune responses in animal models. Always reconstitute slowly by injecting bacteriostatic water down the side of the vial, allowing it to dissolve passively without shaking—mechanical agitation disrupts hydrogen bonding and promotes aggregation.

Absolutely. Subcutaneous injection produces slower, sustained plasma levels compared to intravenous administration, which peaks rapidly and clears faster. Intranasal delivery bypasses first-pass metabolism and delivers peptides directly to the CNS via the olfactory bulb. Semax and Selank are commonly administered intranasally in research settings for this reason. Oral bioavailability is limited for most peptides due to proteolytic degradation in the GI tract; Dihexa is a rare exception with confirmed oral activity. Research design must match delivery route to the peptide's pharmacokinetics. We provide bioavailability and half-life data for every compound to inform protocol development.

Freeze reconstituted aliquots immediately and avoid freeze-thaw cycles. Neurotrophic peptides are particularly susceptible to aggregation and oxidation. Cerebrolysin and Dihexa both contain methionine residues prone to oxidative modification. Store reconstituted peptides in single-use aliquots at −80°C in amber vials with inert atmosphere (nitrogen or argon) if possible. For peptides used within 72 hours, refrigeration at 2–4°C in bacteriostatic water maintains activity, but longer storage requires freezing. Never reconstitute your entire peptide stock at once. We've reviewed failed experiments where investigators lost entire batches to repeated freeze-thaw degradation.

Administer IGF-1 pathway peptides anyway if anabolic resistance is present. Normal serum IGF-1 doesn't indicate normal tissue response. The problem in sarcopenia isn't IGF-1 quantity but skeletal muscle's ability to respond to it. Receptor density decreases by 40% and downstream Akt phosphorylation shows even greater impairment in aging muscle biopsies. IGF 1 LR3 overcomes this resistance by increasing free IGF-1 concentration high enough to saturate the reduced receptor population, driving pathway flux despite decreased signaling efficiency. Measuring grip strength and lean mass changes at 8-week intervals provides better outcome metrics than baseline IGF-1 levels, which correlate poorly with functional sarcopenia severity.

Use subcutaneous or intraperitoneal administration to bypass first-pass degradation and deliver the peptide systemically, allowing it to reach gut tissue via circulation. Oral peptides face proteolytic degradation in the stomach and small intestine; only small, stable sequences like KPV or modified peptides with protease-resistant bonds maintain bioavailability after oral dosing. For peptides requiring direct mucosal contact, consider encapsulation in enteric-coated delivery systems or liposomal formulations that protect the peptide until it reaches the target site.

Check whether the certificate of analysis included sequence verification by mass spectrometry. HPLC purity measures the percentage of total protein that elutes as a single peak, not whether that peak is the correct sequence. A synthesis error at position 3 (wrong amino acid incorporated) will still show 98% purity if the byproducts were removed, but the peptide will have zero bioactivity. The next diagnostic step is circular dichroism spectroscopy to confirm secondary structure, especially for peptides with required alpha-helical or beta-sheet domains. Alternatively, run a positive control using a peptide from a different supplier. If that works, the issue is the compound, not your protocol.

Verify the dosing regimen, treatment duration, and endpoint measurement timing. Tight junction remodeling can take 7–14 days to manifest at the protein level even when signaling changes occur within hours. Confirm the peptide reached target tissue by measuring serum concentrations or using fluorescently labeled analogs. If the peptide is present but ineffective, the mechanism may not interact with the specific tight junction dysfunction present in your model. Zonulin-mediated permeability differs mechanistically from cytokine-driven claudin downregulation.

Discard the vial immediately. Visible particulates indicate aggregation. The peptide has denatured and formed insoluble protein clumps that cannot bind to target receptors. Aggregation occurs when lyophilized peptides contact water too quickly (injecting liquid directly onto powder rather than down the vial wall) or when reconstitution happens at room temperature instead of refrigerated conditions. The aggregated peptide isn't dangerous, but it's pharmacologically inactive. Real Peptides includes reconstitution protocols with every shipment specifying slow addition of bacteriostatic water at 2–8°C. Labs that skip this step often report "no effect" from otherwise valid compounds.

VIP plus phentolamine provides a mechanistic probe. If intracavernosal administration of VIP (which bypasses NO pathways and activates cAMP-mediated smooth muscle relaxation) combined with phentolamine (which removes alpha-adrenergic vasoconstriction) produces a rigid erectile response, the dysfunction is likely vascular or neurogenic with intact smooth muscle. If the combination fails, the issue is cavernosal fibrosis, Peyronie's disease, or venous leak. Structural pathologies that neither NO-dependent nor cAMP-dependent pharmacological interventions can overcome. This diagnostic application is particularly valuable in diabetic and post-prostatectomy populations where multiple dysfunction mechanisms often coexist.

Reduce the dose by 30–50% or pretreat with an antiemetic like ondansetron 30 minutes before peptide administration. Nausea occurs in 30–40% of subjects receiving bremelanotide at standard research doses (1.75 mg subcutaneous), and it reflects melanocortin receptor activation in the brainstem area postrema. The effect is dose-dependent and typically resolves within 4–6 hours. If nausea persists across multiple administrations despite dose reduction, switch to a different mechanism. Kisspeptin or oxytocin. Which do not produce MC4R-mediated nausea.

Plateau likely indicates the targeted mechanism has reached homeostatic correction. Brain fog driven by neuroinflammation resolves once cytokine levels normalize; further peptide administration maintains but doesn't amplify the effect. Consider whether the plateau represents full resolution or partial improvement. If cognitive function remains below baseline despite 8+ weeks of intervention, the remaining deficit may originate from a different mechanism. This is where multi-modal research protocols investigate combinations: pairing an anti-inflammatory peptide (Cerebrolysin) with a mitochondrial peptide (MOTS-C) to address overlapping pathways. Our technical support team works with research labs designing combination protocols to avoid redundant mechanism targeting while maximizing pathway coverage.

This suggests local tissue-level effects without systemic immune modulation. The peptide is acting within the gut mucosa but not altering circulating immune tone. This pattern is common with locally acting peptides like BPC-157 or VIP. If the research goal requires systemic anti-inflammatory effects, consider peptides with documented effects on circulating cytokines, such as Thymosin Alpha 1, or combine the mucosal-acting peptide with a systemic immunomodulator.

Store lyophilized peptides at −20°C in desiccated conditions. Any moisture exposure accelerates degradation. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. A temperature excursion above 8°C for more than 4 hours can denature peptide structure irreversibly, rendering the compound inactive. If you suspect degradation, request a replacement batch and run a pilot assay to confirm receptor binding activity before committing to a full experimental protocol. Mass spectrometry can verify intact molecular weight, but functional assays are the definitive test.

Plan for fresh reconstitution every 21–28 days maximum. Chronic stress models often span 4–8 weeks; using a single reconstituted batch throughout this period risks administering degraded peptide in later weeks, confounding stress-timeline results. Lyophilized peptide vials remain stable at −20°C for months—purchase sufficient vials to reconstitute fresh batches at 3-week intervals. Label each batch with reconstitution date and discard any vial exceeding 28 days post-reconstitution regardless of appearance. Peptide degradation is often invisible—solutions remain clear even as potency drops due to hydrolysis of peptide bonds, particularly at the N- and C-termini.

Verify peptide concentration using UV spectrophotometry at 280nm or BCA assay before concluding lack of efficacy. Dose-response curves for peptides often span three orders of magnitude, and insufficient dosing is the most common cause of null results. Check administration timing: peptides with short half-lives (under 30 minutes) may require administration during specific disease phases rather than prophylactically. Consider species-specific sequence homology. Human peptides may show reduced binding affinity to murine receptors. If the peptide targets a specific signaling pathway (e.g., IL-6 via gp130), confirm that pathway is actually activated in your model by measuring downstream phosphorylation (STAT3, ERK) before peptide treatment.